PARP Inhibitors for Prostate Cancer Patients Who Are Metastatic and Castrate Resistant

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with mCRPC (metastatic castrate resistant prostate cancer) who also have certain genetic mutations (see table below). The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes testing and treatment decision complicated and often confusing.

The comparison table below is meant to help you ask your medical oncologist or urologist better questions as you compare these two treatments and the tests that are needed.

Cancer ABCs suggests you tell your doctor that you would like to do “Shared Decision Making” in this process and in all of your medical decisions.

Better questions will always get you better answers.

Jan Manarite

(see the table below)